PK model [Regulatives / Guidelines]

posted by PharmCat  – Russia, 2020-09-10 20:12 (744 d 05:18 ago) – Posting: # 21915
Views: 2,494

Hi Helmut!

I can be wrong.

I suppose when we have modified release dosage form there are can be some changes in the PK model. We shold take in to accaunt that dissolution profile of form in GI can have own dynamic. For example: if absorbtion of dissoluted drug is high and dissolution is linear we can have something with "plato" profile. So resulting PK profile can be wery surprising.

Complete thread:

UA Flag
Activity
 Admin contact
22,385 posts in 4,684 threads, 1,594 registered users;
online 7 (0 registered, 7 guests [including 6 identified bots]).
Forum time: Sunday 01:31 CEST (Europe/Vienna)

You really don’t know what you don’t know until you write about it.
Then, everyone knows what you don’t know.    Rod Machado

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5